Member Info for DShox

Quite useful AZ took this through initial development and Phase I and have first right of refusal and EML/SGS already done billions in disposals to Roche and others, so have a pretty good idea of what AZD is now worth and how to ensure we get the right price. It's not like AZ will need to "get up to speed" here really is it nor is today's market release "news" to AZ.

Nelson, you do appear particularly clued up on VELA. Your posts very interesting.

be good for VELA to RNS this with more details on the results and commercialisation negotiations - that said, the latter may land imminently and lips will be tight.

One at 0.115p, 2 at 0.12p and the rest above

Back to NT to buy again folks

Take em out!

That's very much my thoughts and many others that counter the trolls on here. Its inexperienced and less financially robust PIs that are most vulnerable. Maybe MMs and these morons spooked a couple of sells, but I am not convinced much. I haven't seen any meaningful sells to cause a drop hence why you can't buy a bean each time MMs have marked down. But alas, if MMs want to give shares away they don't have, I'll be very pleased to take them - I'll sell them back much higher.

every drop, I hit the buy button and get NT'd the first 5 mins. so, I know I have stock that MMs truly, desparately want and is in very very short supply. in this circumstance, on the cusp of a deal with the likes of AZ or Roche to develop and commercialise a globally life saving, urgently needed drug, why would I not wait for the inevitable multiplication of my investment?

pretty clear what is going on - MMs trying desperately to grab PI stock

Yup. Now we either listen to the derampy Mr Market posts or an intelligent person, an expert and leader in this field globally.

Professor Sir Chris Evans, Chairman and CEO of Excalibur - "We are hugely encouraged by this data..."

Professor John Martin of UCL, Chairman of SGS and PI on the Innovate UK grant awarded - "The promising results from this trial indicate that AZD 1656, a simple oral tablet, has the potential to become a new treatment for COVID 19 - independent of viral mutations - initiating a new wave of therapies for clinicians in meeting this global challenge".

The trial was funded by international investors including Mubadala Sovereign Wealth Fund and UK Government via grant.

SGS and EML have indeed now received the results and "in light of the encouraging trial results, will immediately start commercial discussions..."

That's all.

As soon as NT lifts, buyers take out the stock. The only reason this isnt +50% already and on its way to bag is MMs / Mr Market. Just had Phase II results in a globally needed, rare COVID therapeutic with majors circling in an already advanced negotiation. VELA has a significant interest in AZD. Loading up again for monetisation event at this microcap.

Console showing two undisclosed at 0.0116 Bid (?) and on the Ask, 2 at 0.12p and majority now lining up at 0.13p. Don't be fooled, its about to shoot.

don't worry, SGS arent stupid. they, like the rest of us, didn't accept VELA shares to sell anywhere near current sp

nobody's that thick.

not a sausage - theres's BIG demand and Mr Market wants you pesky PIs to supply shares

at this sp, on this news, no frikkin way

...

bought twice - it'll fly in a sec

only on AIM can you get news like this and MMs mark it down - very very easy way to multiply an investment

COVID deaths in UK were diabetics. This is an oral tablet that works regardless of mutation. Hugely valuable globally.

They started commercial discussions months ago and having originally taken this drug from AZ for development and with the EML/SGS directors having inked disposals to Roche and others, I highly doubt they will need Rampant's daily blog to get the word out and deliver shareholder value.

Good post Ohmni. Each to their own de-risking etc! Could be a wise move!

RNS today then?!

Good to see activity on the bb even if its Rampant spamming into the early hours, still trying to claim Friday RNSs are likely poor or mediocre because there's less "media" people around apparently.

I mean, SGS/EML directors will be wholly dependent on Rampant's fantasy column in his local rag to commercialise AZD :) "15 years in media" (trolling LSE bbs)

Nah, I'll stick to the AstraZeneca connection and past deals between EML/SGS directors with Roche to drive the share price on Friday and beyond if the results deliver. Unless of course they land today.